Diethylethanolamine → (2R)-3-[[(2R,3R,4S,5S,6S)-3-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-methyl-5-[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopenten-1-yl)carbamoyl]oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-carbamoyl-4-carbamoyloxy-5-hydroxyoxan-2-yl]oxy-hydroxyphosphoryl]oxy-2-[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylidenenonadeca-2,6,13,17-tetraenoxy]propanoic acid

Participants

Reaction Steps

81 g of 95% pure moenomycin A dissolved in 7 L of aqueous buffer solution, pH 7.9, conductivity 10.5 mS/cm (resulting from DEAE purification and ultrafiltration), are loaded onto a column with a capacity of 2.7 L (W×H=10 cm×35 cm) and packed with MCI GEL® CHP20P. Elution is carried out with a linear gradient from buffer A (m/15 phosphate buffer, pH 7.8) to buffer B (m/15 phosphate buffer, pH 7.8 with 33% 2-propanol). The column flow is fractionated and analyzed. The fractions with at least 98.8% pure moenomycin A are collected and, after removal of the salts as described in Example 4, dried, resulting in 71 g of 99.3% pure moenomycin A with 0.4% moenomycin A12 as concomitant substance.

Provenance & Evidence